X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
94
PharmaCompass offers a list of Primidone API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Primidone manufacturer or Primidone supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Primidone manufacturer or Primidone supplier.
PharmaCompass also assists you with knowing the Primidone API Price utilized in the formulation of products. Primidone API Price is not always fixed or binding as the Primidone Price is obtained through a variety of data sources. The Primidone Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Liskantin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Liskantin, including repackagers and relabelers. The FDA regulates Liskantin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Liskantin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Liskantin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Liskantin supplier is an individual or a company that provides Liskantin active pharmaceutical ingredient (API) or Liskantin finished formulations upon request. The Liskantin suppliers may include Liskantin API manufacturers, exporters, distributors and traders.
click here to find a list of Liskantin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Liskantin DMF (Drug Master File) is a document detailing the whole manufacturing process of Liskantin active pharmaceutical ingredient (API) in detail. Different forms of Liskantin DMFs exist exist since differing nations have different regulations, such as Liskantin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Liskantin DMF submitted to regulatory agencies in the US is known as a USDMF. Liskantin USDMF includes data on Liskantin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Liskantin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Liskantin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Liskantin Drug Master File in Japan (Liskantin JDMF) empowers Liskantin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Liskantin JDMF during the approval evaluation for pharmaceutical products. At the time of Liskantin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Liskantin suppliers with JDMF on PharmaCompass.
A Liskantin CEP of the European Pharmacopoeia monograph is often referred to as a Liskantin Certificate of Suitability (COS). The purpose of a Liskantin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Liskantin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Liskantin to their clients by showing that a Liskantin CEP has been issued for it. The manufacturer submits a Liskantin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Liskantin CEP holder for the record. Additionally, the data presented in the Liskantin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Liskantin DMF.
A Liskantin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Liskantin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Liskantin suppliers with CEP (COS) on PharmaCompass.
A Liskantin written confirmation (Liskantin WC) is an official document issued by a regulatory agency to a Liskantin manufacturer, verifying that the manufacturing facility of a Liskantin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Liskantin APIs or Liskantin finished pharmaceutical products to another nation, regulatory agencies frequently require a Liskantin WC (written confirmation) as part of the regulatory process.
click here to find a list of Liskantin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Liskantin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Liskantin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Liskantin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Liskantin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Liskantin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Liskantin suppliers with NDC on PharmaCompass.
Liskantin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Liskantin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Liskantin GMP manufacturer or Liskantin GMP API supplier for your needs.
A Liskantin CoA (Certificate of Analysis) is a formal document that attests to Liskantin's compliance with Liskantin specifications and serves as a tool for batch-level quality control.
Liskantin CoA mostly includes findings from lab analyses of a specific batch. For each Liskantin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Liskantin may be tested according to a variety of international standards, such as European Pharmacopoeia (Liskantin EP), Liskantin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Liskantin USP).
Market Place
